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Expression of the immediate-early response gene IER2 has been associated with the progression of several types of cancer, but its
functional role is poorly understood. We found that increased IER2 expression in human melanoma is associated with shorter
overall survival, and subsequently investigated the mechanisms through which IER2 exerts this effect. In experimental melanoma
models, sustained expression of IER2 induced senescence in a subset of melanoma cells in a p53/MAPK/AKT-dependent manner.
The senescent cells produced a characteristic secretome that included high levels of the extracellular phosphoglycoprotein
osteopontin. Nuclear localization of the IER2 protein was critical for both the induction of senescence and osteopontin secretion.
Osteopontin secreted by IER2-expressing senescent cells strongly stimulated the migration and invasion of non-senescent
melanoma cells. Consistently, we observed coordinate expression of IER2, p53/p21, and osteopontin in primary human melanomas
and metastases, highlighting the pathophysiological relevance of IER2-mediated senescence in melanoma progression. Together,
our study reveals that sustained IER2 expression drives melanoma invasion and progression through stimulating osteopontin
secretion via the stochastic induction of senescence.
Oncogene; https://doi.org/10.1038/s41388-021-02027-6
INTRODUCTION
The term “immediate-early response” (IER) describes the collective
transient expression of immediate-early genes (IEGs) upon
exposure to a variety of extracellular cues, including growth
factors, mitogens, and stressors such as ultraviolet (UV) irradiation
and toxins [1, 2]. Constitutive IEG expression, for example, caused
by disturbed mitogen-activated protein kinase (MAPK) signaling
that is often found in cancer cells, is associated with tumor
progression and metastasis [3–5].
The immediate early response protein 2 (IER2, also called
ETR101 and CHX1 in humans or Pip92 in the mouse; hereafter
referred to as IER2, regardless of species) is a poorly investigated
IEG that is rapidly but transiently induced in response to a variety
of growth factors, and other mitogenic and differentiation-
inducing stimuli [6–9]. The IER2 protein is short-lived due to
multiple PEST sequences, contains a putative bipartite nuclear
localization signal (NLS), and has limited homology to JunB and
JunD [9, 10]. IER2 possesses no obvious DNA-binding motif but
has been implicated in transcriptional regulation [11]. IER2 has
also been suggested to regulate the activity of the protein
phosphatase PP2A [12]. Cell density influences the subcellular
localization of the IER2 protein, and the release of cells from
contact inhibition results in translocation of IER2 from the
cytoplasm to the nucleus [13]. During embryonic development,
IER2 plays a role in determining left–right asymmetry [14].
We previously reported that IER2 is aberrantly and constitutively
expressed in a wide variety of human tumors in comparison to the
corresponding non-transformed tissue. Ectopic overexpression of
IER2 in poorly metastatic pancreatic tumor cells promoted their
motility and invasiveness in vitro and stimulated metastasis
in vivo. Consistently, we found that IER2 is a predictor of poor
metastasis-free and overall survival of colorectal adenocarcinoma
patients [13]. More recently, others have demonstrated a critical
role for IER2 in the regulation of hepatocellular carcinoma
migration and invasion via an integrin β1-focal adhesion kinase
(FAK)-Src-paxillin signaling pathway and Rho GTPases [15–17], and
in the regulation of endothelial cell motility, cell–matrix adhesion
and in vitro angiogenesis [18]. To date, however, the association
between IER2 expression and tumor progression has not been
explained mechanistically, in particular the consequence of the
constitutive rather than transient expression that is observed in
many cancers.
Here, we report that sustained expression of IER2 in fibroblasts
stochastically induces cellular senescence. Senescence is typified
by durable cell cycle arrest and an enlarged flattened morphology.
The development of senescence involves proliferative arrest in
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response to sustained and robust activation of the p16INK4a–Rb
(retinoblastoma) and/or p53–p21WAF1/CIP1 tumor suppressor path-
ways [19, 20]. Features of senescent cells include an enlarged
morphology, positivity for senescence-associated β-galactosidase,
increased ploidy, and the secretion of a cocktail of pro-
inflammatory cytokines, growth factors and matrix remodeling
enzymes termed the senescence-associated secretory phenotype
(SASP) [21]. The specific content of the SASP depends on the cell
type and the senescence inducer [22, 23].
In the context of cancer, cellular senescence can both restrict
and promote tumorigenesis and progression. On the one hand, it
represents a first-line barrier against neoplastic transformation and
tumor initiation [19, 24, 25]. On the other hand, senescence can
stimulate tumor growth and progression through cell-
autonomous effects such as increasing invasive, tumorigenic,
and cancer cell stemness properties [26, 27], as well as through
non-cell-autonomous effects mediated by the SASP [28], including
the recruitment of immature myeloid cells [29] and the promotion
of metastasis [30].
In the present study, we report that IER2 expression can be
constitutively increased in human melanomas and that this
correlates with poor overall survival. By mimicking this constitutive
expression in experimental models, we show that similar to the
situation in fibroblasts, IER2 induces p53-dependent senescence in
a fraction of melanoma cells and that this is associated with a
characteristic SASP. A major component of the IER2-driven SASP is
osteopontin (OPN), which plays a central role in driving melanoma
cell invasion. These findings reveal an important role for IER2 in
melanoma progression, highlight the role of senescence and the
SASP in this process, and identify potential targets for therapeutic
intervention.
RESULTS
IER2 induces senescence in murine 3T3 fibroblasts
To investigate the impact of sustained IER2 expression on cell
behavior, we engineered mouse 3T3 fibroblasts to inducibly
express IER2 in response to RheoSwitch ligand 1 (RSL-1; hereafter
referred to as RSL), a pharmacologically inert diacylhydrazine
[31–33]. IER2 induction against very low basal levels was achieved
after stimulation of the cells with RSL (Figs. S1a, 1a, 1b), which
reached maximum expression at 6 h and diminished to basal
levels within 48 h (Fig. 1c). To maintain IER2 expression over
periods exceeding 24 h, cells were therefore treated daily with RSL
(Fig. S1b). While sustained RSL-driven IER2 expression had no
effect on viability (Fig. S1c), striking morphological changes and
cell division abnormalities reminiscent of cellular senescence were
observed in a subset of 3T3 cells (Video S1). Consistently,
induction of IER2 expression resulted in increased senescence-
associated β-galactosidase activity in a portion of the cells (Fig. 1d,
e), which is a marker of cellular senescence [34]. Furthermore,
IER2-expressing cells accumulated in the G2/M phase of the cell
cycle and exhibited elevated ploidy (Fig. 1f), again indicative of the
induction of senescence.
To understand the transcriptional response to continuous IER2
expression, we performed differential gene expression profiling of
RSL-treated IER2-inducible 3T3 cells relative to controls. Gene set
enrichment analysis (GSEA) [35] using Kyoto encyclopedia of
genes and genomes (KEGG) and gene ontology biological
processes annotations revealed that IER2-induced genes are
involved in processes, including lipid metabolism, immune/
inflammatory, cytokine production, and cell cycle regulation
(Table S1). Importantly, the expression of TRP53 (mouse homolog
of p53), the main regulator of senescence-associated cell cycle
arrest [36], was increased, together with the p53 signaling
pathway gene set. Correspondingly, expression of MDM2, a
negative regulator of p53 [37] was decreased (Fig. 1g). In addition,
several SASP-associated factors [28] including IL-6, CCL8, CXCL1,
CXCL5, CCL3, and CCL11 were induced in response to IER2,
together with SAA1, which has been reported to amplify the
expression of SASP-related factors via the Toll-like receptors TLR2/
TLR4 [38] (Fig. 1h). Western blotting confirmed increased
expression of p53 in IER2-expressing 3T3 cells, as well as of the
p53-target gene p21waf1/cip1 (hereafter p21) (Fig. 1i). In wild-type
UV-irradiated 3T3 cells, IER2 induction preceded p53 activation
(Fig. S1d) and was required for p53 stabilization (Fig. S1e).
Together, these findings demonstrate that constitutive IER2
expression stochastically promotes senescence in mouse fibro-
blasts, and point to a potential functional relationship between
IER2 and p53.
Constitutive IER2 expression correlates with poor prognosis in
melanoma
Melanoma has high intrinsic potential for dissemination [39] and a
high rate of metastatic spread compared to other cancers [40].
IER2 promotes metastasis and is associated with poor prognosis in
colorectal cancer patients [13]. To investigate whether IER2 might
play a similar role in human melanoma, we analyzed the TCGA
skin cutaneous melanoma dataset. Kaplan–Meier analysis revealed
that melanoma patients with high IER2 expression (Fig. S2a) had a
significantly shorter overall survival compared to patients with
lower IER2 levels (Fig. 2a). To analyze whether high IER2
expression is linked to common driver mutations in melanoma
[41], tumors were stratified based on their BRAF, NRAS, and TP53
mutation status. In line with the mutual exclusivity of BRAF and
NRAS mutations in melanoma [42], we found that high IER2
expression is associated with wild-type BRAF and mutated NRAS.
Importantly, high IER2 expression was almost exclusively asso-
ciated with wild-type p53 status (Fig. 2b), consistent with our
findings that p53 levels are increased in melanoma cells upon
sustained IER2 expression (see below).
To determine whether IER2 expression correlates with the
proliferative or the invasive potential of melanoma cells, we
analyzed a dataset of human melanoma cell lines utilizing the
Heuristic Online Phenotype Prediction algorithm (HOPP) [43–45].
This revealed significantly higher IER2 expression in melanoma
cells that exhibited an intermediate or invasive phenotype (Fig.
S2b, Table S2). Thus, similar to our previous work with pancreatic
tumor cells [13], IER2 expression is associated with enhanced
invasiveness of melanoma cells.
IER2 stochastically induces senescence in melanoma cells via
the p53–p21 axis
To investigate the impact of constitutive IER2 expression in
melanoma, we generated IER2-inducible RheoSwitch B16–F10
(B16) and Ret mouse melanoma cells, which both harbor wild-
type p53 (p53WT) and express only very low levels of IER2. To
control for the effect of p53 status, in the absence of a suitable
melanoma cell line we similarly created IER2-inducible 67NR
mouse breast adenocarcinoma cells, which are p53-deficient
(Fig. S2c) and likewise express very low endogenous levels of
IER2 (Fig. 2c). To achieve sustained IER2 expression over periods
exceeding 24 h, cells were treated with RSL daily (Fig. S2d).
Similar to the case with fibroblasts, induction of IER2 expression
in B16 and Ret cells led to the development of senescence in a
proportion of the cells (Fig. 2d, e), as well as to the accumulation
of cells in the G2/M phase of the cell cycle, and to a higher
number of >4 N polyploid cells (Fig. S2e). By contrast, the p53-
deficient (p53null) 67NR cells remained unaffected by IER2
overexpression (Fig. 2d, e). Importantly, ectopic re-introduction
of wild-type p53 into two independent IER2-inducible 67NR
clonal cell lines enhanced the ability of IER2 to induce
senescence (Fig. S2f–h), indicating that wild-type p53 is required
for the efficient induction of senescence by IER2.















In concordance with the results obtained with mouse 3T3
fibroblasts, ectopic expression of IER2 in B16 cells led to
p53 stabilization and activation, as evidenced by phosphorylation
of p53 on serine 15 and 392. Consistently, IER2 expression resulted
in accumulation of the 48 kDa MDM2 isoform (MDM2-iso), an
MDM2 splice variant that stabilizes/activates p53 through
competitive binding to MDM2-full length (MDM2-FL), which
inhibits the MDM2-FL–p53 interaction and thereby reduces p53
degradation [46–48]. Moreover, the p53 target gene and cell cycle
regulator p21, together with p27KIP1 (p27) were also elevated
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upon IER2 induction (Fig. 2f), consistent with cell cycle arrest.
Unchanged Rb (retinoblastoma) phosphorylation and protein
levels, together with unaffected p16INK4a (p16) levels indicate that
IER2-mediated senescence is independent of the tumor-suppressor
p16-Rb pathway [49] (Fig. S2i). RSL alone had no effect on cellular
morphology, nor on the activation of the p53–p21 axis in control
B16 cells, which were stably transfected with pNEBR-R1 plasmid
alone (B16-R1; Figs. 2f and S2j). IER2 also had no impact on p53
mRNA levels, suggesting that IER2 regulates p53 post-
transcriptionally (Fig. S3a, b). Consistently, p53 inhibition with
pifithrin-α (PFT-α, Fig. 2g–i), as well as siRNA-mediated silencing of
p53 (Fig. S2m, n) abrogated IER2-induced senescence, whereas
stabilization of p53 by the MDM2 inhibitor nutlin-3 (NU-3) elicited a
senescent phenotype in both B16 and Ret cells (Fig. 2g–i).
Next, we investigated whether IER2 is involved in p53 regulation
following genotoxic stress. B16 cells were treated with the
chemotherapy drugs doxorubicin and camptothecin with and
without induction of IER2 expression. Elevated IER2 levels
promoted earlier stabilization and activation of p53, as well as
an earlier increase in p21 levels in response to both chemother-
apeutics (Fig. S2k, l).
Together these data demonstrate that IER2 contributes to p53
regulation under both normal and stress conditions and that p53
is required for IER2-induced senescence.
IER2 requires active AKT and MAPK signaling to promote p53-
dependent senescence in mouse melanoma cells
The RAS–RAF–MEK–ERK (MAPK) and PI3K-AKT (AKT) signaling
pathways are key players in melanoma progression [50].
Oncogenic mutations that hyperactivate ERK and AKT can
promote p53-dependent oncogene-induced senescence in a cell
context-dependent manner [49, 51]. Western blot analysis
revealed rapid activation of both the MAPK and AKT pathways
in response to IER2, as indicated by elevated phosphorylation of
ERK1/2 at threonine 202 and tyrosine 204, and AKT at serine 473
and tyrosine 308 (Fig. 3a). These results suggest that IER2 may
induce senescence via these pathways.
To investigate a possible role for the MAPK and AKT pathways in
IER2-induced senescence, we inhibited the MAPK (MEKi) and AKT
(AKTi) pathways alone and/or in combination in melanoma cells
induced to express IER2, and compared p53 and p21 levels. MEK
inhibition modestly decreased p53/p21 levels compared to
untreated RSL-stimulated cells, while AKT inhibition completely
abrogated IER2-induced p53 stabilization and substantially
reduced p21 levels (Fig. 3b). Furthermore, both AKT and MEK
inhibition abrogated the IER2-induced activation of mTOR (Fig.
3b), which is involved in the induction of senescence via p53
[51, 52]. Consistently, cells expressing IER2 showed a significant
decrease in polyploidy (Figs. 3c, S3c, d) as well as in SA-
β-galactosidase activity in the presence of MEKi and/or AKTi
(Fig. S3e, Fig. 3d).
These results reveal that MAPK and AKT signaling is mechan-
istically linked to IER2-induced senescence in melanoma.
Osteopontin is a major component of the IER2-induced SASP
One of the hallmarks of senescence is the SASP [28, 53]. SASP
factors can promote inflammation and support tumor cell invasion
and metastasis [21, 54, 55]. We, therefore, reasoned that IER2 could
conceivably promote melanoma progression through the induc-
tion of senescence and specific SASP components. To identify the
components of the IER2-induced SASP in B16 cells, we initially
employed a small-scale qRT-PCR screen of common SASP signaling
factors. Although the expression of the core SASP cytokines IL-6
and CXCL15 (mouse homolog of IL-8 [56]) was markedly
upregulated, the expression of other SASP-associated factors
tested including IL-1α, IL-1β, MMP3, CCL2, CXCL1, CXCL2, and
CXCL5 was unaffected (data not shown). To identify other
components of the IER2-induced SASP, we next employed a
broader panel of 84 key genes involved in cancer inflammation
and immunity (Fig. 4a, Table S3). The expression of 20 of these
genes was significantly changed in response to IER2 expression,
including genes previously identified in the transcriptomic analysis
of IER2-expressing 3T3 cells (e.g., MYD88, TLR2, TLR3, TLR4, and IL-
23a). Figure 4b summarizes genes that encode secreted proteins
whose expression was increased more than twofold upon
induction of IER2 expression. These data were validated by qRT-
PCR (Fig. 4c), and also at the protein level for OPN (Fig. S4a).
Together, these data suggest that the IER2-dependent SASP in B16
melanoma cells includes OPN, CXCL15, CCL5, IL-6, and IL-23a.
As OPN was by far the most highly upregulated gene in
response to IER2 expression (Fig. 4a), and is known to play an
important role in tumorigenesis and metastasis [57, 58], sub-
sequent work focused on this gene. To explore the role of p53 in
IER2-induced OPN expression, we treated IER2-inducible B16 and
Ret cells with PFT-α and NU-3 and monitored OPN expression and
secretion. Inhibition of p53 with PFT-α strongly suppressed the
ability of IER2 to induce OPN transcription, while stabilization of
p53 with NU-3 had no significant effect (Ret cells) or even
enhanced OPN expression (B16 cells) (Fig. 4d). Similarly, the
massive IER2-induced secretion of OPN (sOPN, secreted osteo-
pontin) was strongly attenuated by inhibition of p53 with PFT-α,
while it was maintained when cells were treated with NU-3 (Fig.
4e, for anti-OPN antibody specificity, see Fig. S4a).
To validate these findings in human melanoma cells, we
ectopically expressed IER2 in p53wt A375 cells, and in SK-Mel-28
cells, which carry a homozygous loss-of-function mutation in p53
(p53L145R) and therefore have only very low levels of p21
expression [59–61]. OPN expression and secretion, as well as the
percentage of senescent cells, were significantly increased by
ectopic expression of IER2 in p53wt A375 cells, but not in p53L145R
SK-Mel-28 cells (Fig. S4b–d). In addition, the senescence pheno-
type in A375 cells was accompanied by activation of the AKT
Fig. 1 IER2 induces senescence in murine 3T3 fibroblasts. a Schematic representation of the RheoSwitch mammalian inducible expression
system. RheoReceptor-1 (RR) and RheoActivator (RA) expressed from the pNEBR-R1 plasmid regulate transcription of mouse IER2 cloned into
the pNEBR-X1 vector. bWestern blot analysis of IER2 and vinculin (loading control) in three separate clones of NIH/3T3 mouse fibroblasts (3T3-
ind-IER2 #11, #19, and #22), treated with DMSO or 0.2 μM RSL. c Western blot analysis of IER2 and vinculin in 3T3-ind-IER2 #11 cells treated
with 0.2 μM RSL at the indicated time points. d Representative phase-contrast microscopic images (upper panel) and staining for SA-
β-galactosidase (SA-β-gal) activity (blue, lower panel) of 3T3-ind-IER2 #11 cells treated for 3 days with DMSO or RSL (3 × 0.5 μM). Scale bars,
100 μm. e Percentage of SA-β-gal-positive 3T3-ind-IER2 #11, #19, and #22 cells treated either with DMSO or RSL (3 × 0.5 μM). Bars represent
mean+ SEM. More than 1000 cells per condition from 11 to 15 microscopic images were analyzed. f Cell cycle distribution of 3T3-ind-IER2
#11 cells measured by flow cytometry after treatment with DMSO or RSL (3 × 0.5 μM). Bars represent mean+ SEM (n= 3; 30,000 cells per
replicate were analyzed). g, h GSEA enrichment plots and corresponding heat maps of selected differentially expressed genes belonging to
the “p53 signaling pathway” (using KEGG annotations, g) or “Inflammatory response” (using GOBP annotations, h) associated with elevated
IER2 expression. The red and blue colors in the bar-code plot indicate over- and under-expression in the mRNA. NES normalized enrichment
score. i Western blot analysis of IER2, p53, p21, and vinculin in 3T3-ind-IER2 #11 cells treated with either DMSO or RSL (3 × 0.5 μM). Bars
represent vinculin-normalized background-corrected integrated signal densities+ SEM from three biological replicates. Data are normalized
to DMSO-treated cells. Statistical significance was determined by an unpaired Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.
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kinase and p53/p21 pathways, consistent with the results
obtained in murine melanoma cells (Fig. 4e).
Since active ERK and AKT are important for IER2-induced
p53 stabilization and senescence (Fig. 3b–e), we next examined
whether inhibition of both pathways alone or in combination
affects levels of the OPN protein. In contrast to the MEK inhibition,
AKT inhibition resulted in a substantial decrease in secreted OPN
upon IER2 expression both in B16 and Ret cells (Fig. 4f).
Together, these data indicate that sustained expression of IER2
can lead to a characteristic secretory phenotype in melanoma
cells, a major component of which is OPN, which is upregulated in
an AKT/p53-dependent manner.
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IER2-driven OPN is expressed by senescent cells
The above results suggest that IER2 induces senescence stochas-
tically, as senescence was only observed in around 10–25% of the
cells (Figs. 2d, e, S4d). Therefore, we next assessed whether OPN is
secreted by non-senescent (N) or senescent (S) cells after IER2
induction. We took advantage of the increased cellular size of
senescent cells to sort them by flow cytometry-based on forward
and side scatter (Fig. S5a, b). In line with previous results, IER2
induction markedly increased the percentage of enlarged senes-
cent melanoma cells in the flow cytometry (Fig. S5b). The
enrichment of senescent cells in the sorted fraction was confirmed
by re-evaluation post-sorting (Fig. 5a), by monitoring of cellular
morphology and SA-β-galactosidase activity (Fig. 5b), as well as by
cell cycle analysis, including analysis of the percentage of >4 N cells
(Figs. S5c, 5c). The senescence-enriched fraction also exhibited
higher MDM2-iso and p21 levels compared to the non-senescent
fraction (Fig. 5e), reflecting p53 activation. Although IER2 levels
were elevated to the same extent in senescent and non-senescent
cells, OPN was predominantly expressed by the senescent cell-
enriched population (Fig. 5d, e). Notably, in contrast to the non-
senescent fraction that showed higher levels of activated ERK1/2,
the senescence-enriched fraction exhibited enhanced AKT activa-
tion (Fig. 5e). This is consistent with our observation that OPN
secretion is abrogated by AKT inhibition but not ERK inhibition (Fig.
4f). Together, these data indicate that (i) the stochastic induction of
senescence and OPN expression in response to IER2 is not due to
variation in the expression level of IER2 within distinct subpopula-
tions of cells, (ii) that enhanced IER2 expression does not induce
senescence and OPN expression in all cells, and (iii) that OPN is part
of the IER2-induced AKT/p53-dependent SASP.
Fig. 2 IER2 requires p53–p21 to promote senescence in murine melanoma cells. a Kaplan–Meier analysis of the overall survival of the TCGA
skin cutaneous melanoma cohort (n= 471) stratified according to low (IER2low) and high (IER2high) IER2 expression. b IER2 expression in the
skin cutaneous melanoma cohort from (a), with patients stratified according to p53 (left), BRAF (middle) and NRAS (right) mutational status.
The red lines represent the means. c Western blot analysis of IER2 and vinculin (loading control) in B16-ind-IER2 #51, Ret-ind-IER2 #69, and
67NR-ind-IER2 #37 RheoSwitch cells treated either with DMSO or RSL (3 × 0.5–1.0 μM). d Staining for SA-β-galactosidase activity (blue) in B16-
ind-IER2 #51 and 67NR-ind-IER2 #37 cells treated either with DMSO or with RSL (3 × 0.5 μM). Scale bar, 100 μm; inset 25 μm. e Percentage of SA-
β-galactosidase-positive cells in B16-ind-IER2 #51, Ret-ind-IER2 #69, and 67NR-ind-IER2 #37 cells after stimulation with DMSO or RSL (3 ×
0.5–1.0 μM; n= 3). f Western blot analysis of the indicated proteins in parental B16-R1 #2 and B16-ind-IER2 #51 cells after stimulation with
either DMSO or RSL (3 × 0.5 μM). g Representative images of staining for SA-β-galactosidase activity (blue) and h quantification of SA-
β-galactosidase staining in B16-ind-IER2 #51 cells (upper panels) and Ret-ind-IER2 #69 cells (bottom panels) treated with PFT-α (20 μM) or NU-3
(5 μM) with or without stimulation with RSL (3 × 0.5 μM); n= 3. Scale bars, 100 μm. i Western blot analysis of IER2, p53 pS15, p53, and p21 in
B16-ind-IER2 #51 (upper panel) and Ret-ind-IER2 #69 cells (bottom panel) treated as in g. Bars represent mean+ SEM; n= 3. Statistical
significance was determined using an unpaired Student’s t test. n.s. nonsignificant (p > 0.05), *p < 0.05, **p < 0.01, ***p < 0.001.
Fig. 3 IER2 requires active AKT and ERK signaling to promote p53-dependent senescence in melanoma cells. a Western blot analysis of
IER2, AKT phosphorylated on serine 473 (pS473) and threonine 308 (pT308), AKT, ERK phosphorylated on threonine 202/tyrosine 204 (pT202/
Y204), ERK1/2, and vinculin (loading control) in B16-ind-IER2 #51 cells treated with DMSO or RSL (3 × 0.5 μM), harvested at indicated time
points after the last dose of RSL. b Western blot analysis of the indicated proteins in B16-ind-IER2 #51 cells treated with MEKi (3 × 1 μM) and/or
AKTi (3 × 1 μM), with or without stimulation with RSL (3 × 0.5 μM). c DRAQ5 labeling of nuclear DNA followed by flow cytometry quantification
of >4 N B16-ind-IER2 #51 cells treated either with DMSO or with RSL (3 × 0.5 μM) in combination with MEKi (3 × 1 μM) and/or AKTi (3 × 1 μM).
d Percentage of SA-β-galactosidase-positive B16-ind-IER2 #51 cells treated as in (c). Bars represent means+ SEM; n= 3. Statistical significance
was determined using an unpaired Student’s t test. n.s. nonsignificant (p > 0.05), *p < 0.05, **p < 0.01, ***p < 0.001.
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Fig. 4 Osteopontin is a major component of the p53-dependent IER2-induced SASP. a Heatmap showing the top IER2-induced genes in
B16-ind-IER2 #51 cells treated either with DMSO or RSL (3 × 0.5 μM) assessed using a Mouse Cancer Inflammation and Immunity Crosstalk PCR
Array. b IER2-induced genes based on the qRT-PCR analysis (CXCL15, IL-6) and the Mouse Cancer Inflammation and Immunity Crosstalk PCR
Array (OPN, Ccl5, and IL23a). Only genes with a fold change (FC) ≥ 2.0 and p < 0.05 are shown. See also Table S3. c qRT-PCR quantification of
IER2, OPN, IL-23a, IL-6, and CCL5 in B16-ind-IER2 #51 cells treated with either DMSO or RSL (3 × 0.5 μM). RPLP0 was used for normalization. Bars
represent means+ SEM; n= 3. d qRT-PCR quantification of OPN in B16-ind-IER2 #51 and Ret-ind-IER2 #69 cells treated with PFT-α (20 μM) or
NU-3 (5 μM) with or without stimulation with RSL (3 × 0.5 and 1 μM). RPLP0 was used for normalization in qRT-PCR. Bars represent mean+
SEM; n= 3. e Western blot analysis of intracellular OPN (iOPN), IER2, p53, p21, vinculin (loading control), and secreted OPN (sOPN) present in
conditioned media (CM) of B16-ind-IER2 #51 and Ret-ind-IER2 #69 cells treated with PFT-α (20 μM) or NU-3 (5 μM), with or without stimulation
with RSL (3 × 0.5 and 1 μM). f Western blot analysis of intracellular OPN (iOPN), IER2, vinculin, and secreted OPN (sOPN) present in conditioned
media (CM) of B16-ind-IER2 #51 and Ret-ind-IER2 #69 cells treated with or without RSL (3 × 0.5 and 0.5 μM) in the presence or absence of MEKi
and/or AKTi (both 3 × 1 μM). Statistical significance was determined using an unpaired Student’s t test. *p < 0.05, **p < 0.01.
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Fig. 5 IER2 only induces osteopontin expression in senescent cells. a B16-ind-IER2 #51 cells were sorted into non-senescent (N) or
senescent (S) cells, and enrichment of the corresponding types of cells in the sorted fractions was controlled by immediate post-sorting flow
cytometry analysis. Bars represent means+ SEM from three independent sorts. b Representative images showing cellular morphology and
SA-β-galactosidase (SA-β-gal) activity (blue) in RSL-treated (3 × 0.5 μM) unsorted (U), sorted non-senescent (N) and sorted senescent (S) B16-
ind-IER2 #51 cells. DMSO-treated cells were used as a control. Scale bar, 100 μm. c DRAQ5 labeling of nuclear DNA followed by flow cytometry
quantification of >4 N B16-ind-IER2 #51 cells treated and sorted as in (b). See also Fig. S5c for the complete cell cycle profile. Bars represent
mean+ SEM, n= 3. d, e qRT-PCR quantification of IER2 and OPN (d) and Western blot analysis (e) of the indicated proteins in RSL-treated (3 ×
0.5 μM) unsorted (U), sorted non-senescent (N) and sorted senescent (S) B16-ind-IER2 #51 cells. RPLP0 was used for normalization. DMSO-
treated cells were used as a control. Bars in (e) represent mean+ SEM; n= 5. f Schematic depiction of the sorting strategy for B16-ind-
IER2#51 cells treated before and after sorting either with DMSO or RSL (3 × 0.5 μM). g B16-ind-IER2 #51 cells were treated for 3 days (3 × 0.5 μM)
with RSL and sorted into non-senescent and senescent populations, each of which was subsequently treated for 3 days with DMSO or RSL
(3 × 0.5 μM), followed by SA-β-gal staining. Bars represent mean+ SEM; n= 4. Statistical significance was determined using an unpaired
Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.
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To investigate whether the sorted non-senescent IER2-expres-
sing B16 and Ret cells are resistant to IER2-induced senescence,
they were exposed to an additional round of either DMSO or RSL
treatment (Fig. 5f). IER2 induced senescence in these cells to the
same extent (~25%) as in the non-sorted parental population (Fig.
S5d, Fig. 5g). The sorted senescent cell-enriched fraction failed to
revert to a non-senescent phenotype when IER2 expression was
no longer maintained. Moreover, an additional round of RSL
stimulation further increased the percentage of senescent cells in
this fraction (Fig. S5d, Fig. 5g).
Overall, these data suggest that IER2 expression leads to
stochastic senescence development in a fraction of melanoma
cells, which elicits the production of OPN.
IER2 nuclear localization is critical for senescence
development and OPN secretion
IER2 contains a putative bipartite NLS [9] that is conserved across
species (Fig. S6a). To investigate whether the subcellular localiza-
tion of IER2 is important for the induction of senescence and OPN
secretion, we generated a RheoSwitch B16 cell line inducible for
IER2 with a mutation in the first part of the putative NLS (IER2-
mNLS, Fig. S6b). To be able to determine the effect of wild-type
IER2 (IER2-wt) vs. mutated IER2-mNLS, we first titrated the RSL
concentration required to achieve comparable induction of IER2 in
both cell lines (Fig. 6a). Unexpectedly, IER2-mNLS exhibited altered
electrophoretic mobility in sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE), producing two immunoreactive
Fig. 6 Nuclear localization of IER2 is required for senescence induction and osteopontin secretion. aWestern blot analysis of the indicated
proteins in B16-ind-IER2 #51 and B16-ind-IER2-mNLS #56 cells, treated with RSL at the indicated concentrations. DMSO was used as a control.
b qRT-PCR quantification of IER2 in B16-ind-IER2 #51 (treated with DMSO or 0.25 μM RSL) and B16-ind-IER2-mNLS #56 cells (treated with DMSO
or 5 μM RSL). RPLP0 was used for normalization. Bars represent mean+ SEM; n= 4. c Quantification of SA-β-galactosidase (SA-β-gal)-positive
B16-ind-IER2 #51 cells (treated with DMSO or 3 × 0.25 μM RSL) and B16-ind-IER2-mNLS #56 cells (treated with DMSO or 3 × 5 μM RSL). Bars
represent mean+ SEM; n= 3. d DRAQ5 labeling of nuclear DNA followed by flow cytometry-based cell cycle analysis of B16-ind-IER2-mNLS
#56 cells after treatment with DMSO or RSL (3 × 5 μM). Bars represent mean+ SEM; n= 3; 30,000 cells were analyzed per replicate. e, f qRT-PCR
quantification of OPN (e) and Western blot analysis (f) of IER2, intracellular OPN (iOPN), p53, p21, vinculin, and secreted OPN (sOPN) in
conditioned medium (CM) in B16-ind-IER2 #51 (treated with DMSO or 3 × 0.25 μM RSL) and B16-ind-IER2-mNLS #56 cells (treated with DMSO
or 3 × 5 μM RSL). Bars represent mean+ SEM; n= 4. Statistical significance was determined using an unpaired Student’s t test. n.s.
nonsignificant (p > 0.05), *p < 0.05, **p < 0.01.
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bands, indicative of possible changes in posttranslational mod-
ifications as a result of altered structure or cellular localization.
Equivalent IER2 expression was further confirmed by qRT-PCR (Fig.
6b). Immunofluorescence staining of B16 cells expressing IER2-wt
and IER2-mNLS confirmed that IER2-wt is partially localized in the
nucleus, whereas IER2-mNLS is restricted to the cytoplasm (Fig.
S6c).
In contrast to IER2-wt, IER2-mNLS induction failed to increase
the levels of p53, MDM2-iso, and p21, or to activate the ERK and
AKT kinases (Fig. 6a), and did not induce senescence (Fig. S6d, Fig.
6c) or result in alterations in the cell cycle (Fig. 6d). Furthermore,
the nuclear localization of IER2 was crucial for the development of
the IER2-induced SASP, as IER2-mNLS induced no, or only a much
weaker upregulation of the IER2-wt-dependent SASP factors,
including OPN (Figs. 6e, f, S6e).
Collectively, these data support the notion that the nuclear
localization of IER2 is required for induction of senescence, as well
as for production of the IER2-specific SASP that includes OPN.
IER2 promotes melanoma migration and invasion via secreted
OPN
We have previously reported that IER2 is rapidly translocated to
the nucleus of actively migrating pancreatic tumor cells after relief
of contact inhibition [13]. Therefore, we next assessed whether the
nuclear localization of IER2 impacts the migration of B16 cells. The
proliferation of B16 cells expressing IER2-wt was lower than that of
IER2-mNLS-expressing cells (Fig. S7a). However, the migration of
cells expressing IER2-wt was enhanced in comparison to IER2-
mNLS-expressing cells (Fig. S7b). We also investigated whether the
nuclear localization of IER2 promotes melanoma invasion. Again,
expression of IER2-wt strongly promoted melanoma cell invasion,
whereas expression of IER2-mNLS even suppressed invasion,
rather than promoting it (Fig. 7a).
To dissect the role of OPN in IER2-mediated invasion, we
generated IER2-inducible B16 cells with CRISPR/Cas9-mediated
knockout of OPN (OPN-KO, Fig. 7b, Fig. S7f). These cells retained
the ability to induce p53 and to develop a senescence phenotype
upon IER2 induction (Figs. 7b, S7c, d). IER2 expression, as well as
the absence of OPN, had no effect on proliferation in these cells
(Fig. S7e). By contrast, deletion of OPN completely abrogated the
ability of wild-type IER2 to promote melanoma cell invasion (Fig.
7a, S7f, g).
Senescent fibroblasts can stimulate the invasiveness of malig-
nant epithelial cells via paracrine signaling [62]. Therefore, we next
assessed whether conditioned medium (CM) from IER2-expressing
B16 cells can affect the migration and invasion of parental, non-
senescent B16 cells. CM from IER2-wt-expressing cells robustly
induced the migration and invasion of parental B16 cells (Fig. 7c,
d). By contrast, CM from IER2-mNLS-expressing cells or from IER2-
wt-expressing cells with a knockout of OPN (OPN-KOs) had no
impact on the migration and invasion of parental, non-senescent
B16 cells (Fig. 7c, d). Interestingly, CM from IER2-wt-expressing B16
cells had no effect on the migration, invasion or soft agar growth
of normal melanocytes (Fig. S8a–d), demonstrating that the IER2-
driven secretome is not sufficient to modify the transformation
status or invasive behavior of non-malignant melanocytes.
Together, these results demonstrate that IER2 fosters melanoma
cell migration and invasion in a manner that requires nuclear
localization of the IER2 protein. IER2-induced OPN expression
mediates these effects and can act in a paracrine manner on
neighboring, non-senescent cancer cells.
IER2 levels correlate with OPN expression in human
melanoma
To gain insight into the association between the IER2-p53 axis and
OPN expression in human melanoma, we first performed
immunohistochemistry analysis of IER2 and OPN expression in
tissue biopsies from patients with primary melanomas. Immuno-
staining of serial sections revealed co-expression of IER2 and OPN
in melanoma nests (Fig. 8a). To investigate the relationship
between IER2 and OPN expression during melanoma progression,
we analyzed tissue microarrays (TMAs) containing human
melanocytic nevi (MN), primary melanomas (primary tumors, PT),
and distant melanoma metastasis (DM). Expression intensity and
abundance were assessed in a blinded fashion by two indepen-
dent researchers using a defined immunohistochemical score for
each probe (Fig. S9a). This analysis demonstrated a significant
upregulation of both IER2 and OPN protein expression in primary
melanomas, compared to MN, and further upregulation of OPN in
distant metastases (Fig. 8b, for clinicopathological data, see Table
S4). These observations are consistent with previous reports
showing that OPN expression correlates with melanoma invasion
[63]. Furthermore, our TMA analysis revealed a significant
correlation between IER2 and OPN protein expression in MN, PT,
and distant metastases (Fig. 8c, for clinicopathological data, see
Table S4).
We next aimed to determine whether IER2 and OPN expression
is linked to a p53/p21-driven senescence-like state in melanomas,
as suggested by our results using melanoma cell lines. Since the
paraffin embedding used for the TMA samples destroys
β-galactosidase activity, we used p53 status combined with p21
expression (p53pos/p21high versus p53neg/p21low, see Fig. S9b, c for
IHC staining) as a surrogate marker of senescent cells. Importantly,
both IER2 and OPN showed significantly higher expression in
patients with an active p53–p21 pathway (p53pos/p21high),
consistent with our findings that demonstrate a functional link
between IER2, p53, and OPN (Fig. 8d, for clinicopathological
information, see Table S5).
Taken together, these data provide evidence that the p53-
dependent IER2-induced senescence and OPN expression, we
observed in cultured melanoma cells, reflects the situation in
human melanoma.
DISCUSSION
Here, we report that high levels of IER2 in human melanoma
samples correlate with increased p53/p21 and OPN levels, as well
as with poor patient prognosis. Mechanistically, we show that IER2
upregulates p53 protein expression via increased expression of
MDM2-iso and enhanced activation of AKT and ERK1/2, which
leads to the stochastic induction of senescence in melanoma cells.
The senescent cells express a characteristic SASP, a major
component of which is OPN. OPN from the senescent cells acts
in a paracrine manner to promote motility and invasion of non-
senescent melanoma cells (Fig. 8e).
Our data suggest that constitutive expression of IER2 on the one
hand leads to accumulation of MDM2-iso, and on the other to
increased activation of AKT and ERK1/2, all of which leads to
stabilization of p53 and expression of p21 (Fig. 8e). These data are
consistent with the induction of premature senescence that is
observed in response to constitutive MEK/MAPK signaling [64],
and with the DNA damage-independent increase in p53 levels and
senescence that are induced via mTORC1 in response to PI3K/AKT
pathway activation [51]. Activation of AKT, which can be
promoted by IER2 [17], also increases intracellular ROS levels by
inducing oxygen consumption or by inhibiting the forkhead box O
(FOXO) family of transcription factors, which further fosters cellular
senescence [65, 66].
Our data indicate that OPN is a major component of the IER2-
induced SASP in melanoma. OPN has previously been identified in
some but not all SASPs in a context-dependent manner. OPN is a
component of the bleomycin-induced senescence SASP that is
produced independently of DNA damage, and can also be
produced by senescent stromal cells within the tumor micro-
environment [67, 68]. OPN is additionally produced by senescent
pulmonary artery smooth muscle cells and contributes to the
L. Kyjacova et al.
10
Oncogene
progression of pulmonary hypertension [69]. Context-dependent
inclusion of OPN in the SASP presumably reflects the fact that
multiple signaling pathways regulate the SASP, including the DDR,
p38 MAP kinase, and cGAS/STING pathways [70]. Our data indicate
that AKT plays an important role in regulating the IER2-induced
SASP that includes OPN, which is consistent with the observation
that the downstream AKT target mTOR controls the senescent
secretome through regulating the stability of SASP mRNAs [71]. In
bleomycin-induced senescence, the transcription factors c-Myb
and C/EBPb drive OPN expression [72]. OPN expression in
bleomycin-treated senescent fibroblasts is independent of p53
and Rb [68], but our results show that the IER2-induced SASP,
including OPN expression, is p53 dependent in melanoma cells,
which is consistent with the direct activation of OPN transcription
by p53 [73].
The association between IER2, p53/p21, and poor prognosis in
melanoma patients suggests that IER2-induced senescence
contributes to tumor progression. This could be mediated at a
Fig. 7 IER2 promotes melanoma cell migration and invasion in vitro in an osteopontin-dependent manner. a Invasion of B16-ind-IER2 #51,
B16-ind-IER2-OPN-KO #24, B16-ind-IER2-OPN-KO #28, and B16-ind-IER2-mNLS #56 (IER2-mNLS) cells seeded in DMEM/1% FBS and treated
either with DMSO or RSL (5 × 0.5 μM in the case of IER2-wt or 30 μM in the case of IER2-mNLS cells). Data represent relative invasion through a
Matrigel layer (0.8 mg/ml) towards DMEM/10% FBS at 64 h and are shown as mean+ SEM; n= 3. Data are normalized to DMSO-treated
controls. b Western blot analysis of intracellular OPN (iOPN), IER2, p53, β-actin (loading control), and secreted OPN (sOPN) in conditioned
medium (CM) in B16-ind-IER2 #51 (IER2-wt) cells, as well as in B16-ind-IER2-OPN-KO #24 (IER2-wt/OPN-KO #24) and B16-ind-IER2-OPN-KO #28
(IER2-wt/OPN-KO #28) cells, in which osteopontin was deleted through CRISPR/Cas9-mediated gene inactivation, treated either with DMSO or
RSL (3 × 0.5 μM). c Migration of wild-type B16–F10 cells 32 h after removal of silicone inserts in the presence of CM from B16-ind-IER2 #51, B16-
ind-IER2-OPN-KO #24, B16-ind-IER2-OPN-KO #28, and B16-ind-IER2-mNLS #56 cells treated either with DMSO or RSL (3 × 0.5 μM in case of IER2-
wt or 30 μM in case of IER2-mNLS cells). Data represent relative migration+ SEM from 3 to 4 biological replicates normalized to DMSO-treated
controls. Scale bar, 100 μm. d Invasion of wild-type B16–F10 cells in the presence of CM from B16-ind-IER2 #51, B16-ind-IER2-OPN-KO #24, B16-
ind-IER2-OPN-KO #28, and B16-ind-IER2-mNLS #56 cells that were seeded in DMEM/1% FBS and treated either with DMSO or RSL (5 × 0.5 μM in
the case of IER2-wt or 30 μM in the case of IER2-mNLS cells). Data represent relative invasion through a Matrigel layer (0.8 mg/ml) toward
DMEM/10% FBS at 48 h and are shown as mean+ SEM; n= 3. Data are normalized to DMSO-treated controls. n.s. nonsignificant (p > 0.05),
*p < 0.05, **p < 0.01, with significance determined by an unpaired Student’s t test.
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number of levels. There is increasing evidence that subpopula-
tions of senescent tumor cells may be able to revert to a
proliferative state [74]. Senescent tumor cells that resume
proliferation have been reported to be more aggressive [26],
and to be reprogramed into self-renewing, tumor-initiating cells
[75]. Furthermore, the IER2-induced SASP in the senescent
subpopulation of cells could conceivably stimulate the growth
and aggressiveness of non-senescent tumor cells. In particular,
OPN secreted into the tumor microenvironment has been
reported to promote tumor growth and metastasis in a number
of ways. Through activating receptors such as integrins and CD44,
OPN can foster survival, proliferation, motility, and invasion of
tumor cells, and can stimulate angiogenesis [58]. Consistently, we
found that OPN in the IER2-induced SASP produced by senescent
Fig. 8 High IER2 levels are associated with increased osteopontin levels and p53/p21 expression in human melanoma samples. a
Representative images of serial sections of melanoma nests (Clark level IV) stained with IER2 and OPN. Scale bar, 50 μm. b TMA
immunohistochemistry (IHC) scores for IER2 (left) and OPN (right) for melanocytic nevi (MN, n= 20), primary tumors (PT, n= 46 for IER2 and 48
for OPN), and distant metastases (DM, n= 56 for IER2 and 63 for OPN). Data represent mean+ SEM. c Correlation analysis of IER2 and OPN
expression-based IHC analysis of human melanoma TMAs stratified into melanocytic nevi, primary melanomas, and distant metastases. The
coefficient of determination (R2) of linear regression analysis, the p value of Pearson correlation analysis, and the number of samples analyzed
are indicated for each graph. d TMA immunohistochemistry (IHC) scores for IER2 (left) and OPN (right) in specimens stratified according to
p53/p21 status (inactive: p53neg/p21low, n= 26; active: p53pos/p21high, n= 9). e Scheme illustrating molecular functions of IER2 in melanoma.
Data represent mean+ SEM. n.s. nonsignificant (p > 0.05), *p < 0.05, **p < 0.01, ***p < 0.001. In b and d, statistical significance was determined
using an unpaired Student’s t test.
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melanoma cells is able to stimulate the motility and invasion of
non-senescent melanoma cells in a paracrine manner. This is in
line with a large body of prior work demonstrating a pro-invasive
effect of OPN on tumor cells, mediated by a diverse set of
molecular mechanisms [58]. Furthermore, OPN can also recruit
myeloid-derived suppressor cells and other bone marrow-derived
cells to the tumor microenvironment and metastatic niches,
thereby suppressing anticancer immunity and promoting metas-
tasis [76–78]. Moreover, OPN can reprogram normal fibroblasts
into tumor-promoting cancer-associated fibroblasts [79].
IER2 could conceivably induce senescence through several
mechanisms. Our data clearly show that IER2-induced senescence
and OPN production is p53-dependent and requires nuclear
localization of the IER2 protein. This is consistent with a proposed
transcriptional regulatory role of IER2 [11], with putative IER2
target genes possibly activating senescence-inducing pathways.
IER2 can also regulate the substrate specificity of phosphatase
PP2A [12]. As PP2A activity has been implicated in the induction of
senescence [80, 81], this suggests a possible further mechanism
through which IER2 might induce senescence. In addition, our
time-lapse data suggest that IER2-induced senescence may be
associated with incomplete or delayed cytokinesis (Video S1).
Defective cytokinesis can increase p53 levels via proteolytic
cleavage of MDM2 [82], induce senescence [83, 84], and result
in tetraploidy [85], all of which are features we observed upon
continuous induction of IER2 expression. It is, therefore, con-
ceivable that constitutive IER2 expression may perturb cytokinesis
and thereby induce senescence. In this regard, we note that the
AKT pathway, which we show is activated by IER2, is involved in
context-dependent cytokinesis failure [86]. Defective cytokinesis
can also result in aneuploidy in cancer cells, which fosters
genomic instability that can drive tumorigenesis [85, 87] and thus
may represent a further mechanism through which IER2-induced
senescence might conceivably promote cancer progression if cells
are subsequently able to re-enter the cell cycle.
IER2 induces senescence in only a subpopulation of melanoma
cells, despite the fact that all cells induced with RSL express IER2
(Fig. 5e). This could conceivably reflect heterogeneity in the
melanoma cell populations, yet this seems unlikely, as the IER2-
inducible cells underwent two rounds of single-cell cloning before
experiments were performed. The production of SASP compo-
nents above a given threshold by individual cells may be decisive,
as several SASP components can establish and reinforce the
senescence phenotype through autocrine positive feedback loops
[88–90]. In addition, recently published single-cell tracking
experiments suggest that heterogeneity in the decision of
whether or not cells enter senescence is determined by
differences in the dynamics of p21 expression at particular cell
cycle phases [91]. Similarly, the stochastic induction of senescence
has been associated with the kinetics of p53 expression, with
pulsed p53 expression resulting in reversible arrest, while
continuous p53 expression results in senescence [92]. Thus the
stochastic induction of senescence upon continuous IER2 expres-
sion that we observed may be a consequence of cell fate decisions
that are made in response to the kinetics of expression of key
regulatory proteins such as p21 and p53 at particular phases of
the cell cycle. This notion would be consistent with the
observation that a proportion of sorted non-senescent cells that
have expressed IER2 constitutively over at least two cell cycles can
nevertheless still be induced to enter senescence upon continued
IER2 induction (Fig. 5f, g).
Our findings may have clinical relevance at a number of levels.
We found that increased IER2 expression is associated with high
p53/p21 levels in human melanoma samples, which would be
consistent with the induction of senescence observed in vitro.
Furthermore, IER2 expression is associated with enhanced OPN
expression in human melanoma and also correlates with poor
prognosis. IER2, the IER2-induced SASP including OPN, as well as
IER2-induced senescent cells themselves may therefore represent
therapeutic targets in melanoma. Given the extensive literature
documenting the tumor-promoting role of OPN, blocking the
activity of the OPN protein or inhibiting activation of its receptors
using small molecules have been suggested as possible ther-
apeutic approaches [93]. As OPN has been implicated in fostering
chemoresistance, possibly through autophagy or suppressing
apoptosis [58], IER2-induced OPN expression may also represent a
mechanism that fosters resistance to chemotherapy. Furthermore,
senescent cells exhibit resistance to apoptosis [70], and IER2-
induced senescence may therefore render melanoma cells
intrinsically resistant to chemotherapy-induced apoptosis, as well
as through the production of OPN in the SASP. This may be
relevant to the development of therapy resistance, as transient
chemotherapy-induced senescence has been reported to render
cancer cells more aggressive if they are able to subsequently re-
enter the cell cycle [26, 27]. Together, these observations suggest
that targeting IER2-induced senescent melanoma cells may
improve therapeutic outcomes. A number of senolytic drugs that
aim to clear senescent cells by inducing apoptosis are currently
under development, and the first is already in clinical trials [94].
In summary, these data suggest that aberrant activation of the
IER2–p53–OPN axis in melanoma represents a pathophysiological
mechanism that can contribute to the aggressive behavior of
melanoma cells.
MATERIALS AND METHODS
Cell lines and molecular cloning
The human melanoma cell lines A375, SK-Mel-28, and HT144 as well as NIH
3T3 mouse fibroblasts (3T3) and B16-F10 mouse melanoma cells (B16)
were all from American Type Culture Collection (ATCC, Manassas, VA, USA).
SK-Mel-147 and SK-Mel-23 were from Memorial Sloan Kettering Cancer
Center (NY, USA). Mouse melanoma Ret cells [95] were provided by V.
Umansky. 67NR mouse mammary carcinoma cells [96] were established by
Dr. Fred Miller and kindly provided by E. Lukanidin (Danish Cancer Society,
Copenhagen, Denmark). NIH 3T3 RheoSwitch cells (clones 3T3-ind-IER2
#11, #19, and #22) have been described previously by us [31]. All
melanoma and fibroblast cell lines were cultivated in DMEM containing
4.5 g/l glucose (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum (FBS; Sigma Aldrich, St. Louis, MO, USA) and 1% penicillin/
streptomycin sulfate (Gibco, Carlsbad, CA, USA). Mel-STV human melano-
cytes [97] were cultured in DMEM supplemented with 5% FBS and 1%
penicillin/streptomycin. Melan-a murine melanocytes (Merck, Darmstadt,
Germany) were cultured in RPMI 1640 medium (Gibco, Carlsbad, CA, USA)
supplemented with 10% FBS and 200 nM phorbol-12-myristate-13-acetate
(AdipoGen, San Diego, CA, USA). Cells were kept at 37 °C in an atmosphere
with 5% CO2 and 95% humidity. The human cancer cell lines were
authenticated by the vendor. Mycoplasma contamination was routinely
checked in the laboratory by PCR analysis and all cell lines used in the
study were confirmed to be mycoplasma negative.
The RheoSwitch two-plasmid system for inducible expression of
mammalian genes was purchased from New England Biolabs (Ipswich,
MA, USA). pcDNA3.1-empty and pcDNA3.1-TP53 were provided by Dr.
Takashi Tokino [73]. The pcDNA3.1/V5-His-IER2 plasmid was generated
previously [13] by cloning human IER2 cDNA into pcDNA3.1/V5-His empty
vector (Invitrogen, Thermo Fischer Scientific, Waltham, MA, USA). All
constructs were verified by sequencing.
B16-ind-IER2 #51, Ret-ind-IER2 #69, 67NR-ind-IER2 #37, and 67NR-ind-
IER2 #82 cell clones were prepared by transfection of RheoSwitch B16-
pNEBR-R1, Ret-pNEBR-R1, and 67NR-pNEBR-R1 cells with a pNEBR-X1-IER2
plasmid, containing cloned mouse IER2 cDNA [31]. B16-ind-IER2-mNLS #56
cells were prepared by transfection of RheoSwitch B16-pNEBR-R1 cells
with a pNEBR-IER2 plasmid, containing IER2 cDNA mutated in the NLS
using the Stratagene QuikChange Site-Directed Mutagenesis Kit (Agilent
Technologies, Santa Clara, CA, USA) according to the manufacturer’s
instructions. All cells were transfected using Lipofectamine2000 (Thermo
Fisher Scientific, Waltham, MA, USA) following the manufacturer’s
instructions, and selected with G418 (500–700 µg/ml; Roche Applied
Science, Penzberg, Germany) and hygromycin (500 µg/ml; Merck,
Darmstadt, Germany) as appropriate. Single-cell colonies were expanded
and tested for IER2 expression.
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For live cell imaging, 3T3-IER2-H2B-GFP cells were generated as follows.
IER2-inducible 3T3 #11 cells [98] were stably transfected with the pBOS-
H2B-GFP expression plasmid (BD Pharmingen, New Jersey, USA). Live cell
imaging was performed using an Olympus IX50 inverted microscope
equipped with an F-View II imaging system and Cell^P imaging software
(Olympus, Shinjuku, Tokyo, Japan).
B16-ind-IER2-OPN-KO #24, #28, #33, and #36 cells were generated by
CRISPR/Cas9-mediated targeting of OPN, following published protocols
[99]. Briefly, One-Shot Stbl3 Chemically Competent Escherichia coli cells
(Invitrogen, Thermo Fischer Scientific, Waltham, MA, USA) were trans-
formed with pSpCas9(BB)-2A-Puro V2.0 plasmid (Addgene, #62988),
containing three sgRNA pairs, designed at http://crispr.mit.edu/, targeting
the mouse osteopontin (Spp1) locus. B16-ind-IER2 #51 cells were
transfected with sequence-verified plasmids and pulse-selected with
puromycin for 72 h (InvivoGen, San Diego, CA, USA). Cells were tested
for osteopontin expression using qRT-PCR and Western blotting. The top-
scoring sgRNA pair (sgRNA-top: 5′-cac cgA AGC TAT CAC CTC GGC CGT T-
3′; sgRNA-bottom: 5′-aaa cAA CGGC CGAG GTGA TAGC TTc-3′) was used to
generate single-cell clones.
Chemicals and cell treatments
Cells were treated with the following reagents at the indicated
concentrations. Doxorubicin hydrochloride (Doxo, 2 μM) and camptothecin
(CPT, 2 μM) were purchased from Sigma-Aldrich/Merck (Darmstadt,
Germany). Nutlin-3(a) (NU-3, 5 μM) and Pifithrin-α (PFT-α, 30 μM) were
purchased from Biomol (Hamburg, Germany). RheoSwitch Ligand 1 (RSL,
0.2–30 μM) was purchased from New England Biolabs (Ipswich, MA, USA)
and Exclusive Chemistry Ltd. (Obninsk, Russia). The MEK/ERK inhibitor
Selumetinib (AZD6244; MEKi, 1 μM) was purchased from Selleckchem
(Münich, Germany) and the AKT inhibitor (AKTi, 1 μM) from Sigma-Aldrich/
Merck, #A6730 (Darmstadt, Germany). 3T3 cells were irradiated with 30 J/
m2 UV-C (245 nm) and cells were harvested 1 h after the irradiation.
SDS-PAGE and Western blotting
Cells were washed twice with phosphate-buffered saline (PBS), harvested
into hot SDS sample lysis buffer (4% SDS, 125mM Tris-HCl pH 6.8, 20%
glycerol in double-distilled H2O) containing Complete Protease Inhibitor
Cocktail (Roche Applied Science, Penzberg, Germany), and sonicated using
a Soniprep 150 disintegrator (MSE, London, UK). Protein concentration was
determined using the BCA Protein Assay Kit (Pierce Biotechnology, IL,
Rockford, USA). DTT (100mM final concentration) and 0.01% bromphenol
blue were added to lysates before separation by SDS-PAGE. The same
protein amount (30–50 μg) was loaded into each well. Proteins were
electrotransferred onto a nitrocellulose membrane (GE Healthcare, Little
Chalfont, UK) at 4 °C overnight using wet transfer. Specific proteins were
detected using primary antibodies (overnight incubation at 4 °C) followed
by horseradish peroxidase-conjugated secondary antibodies (2–4 h incu-
bation at 4 °C). Peroxidase activity was detected by enhanced chemilumi-
nescence (ECL; Pierce Biotechnology, Rockford, IL, USA). GAPDH, vinculin,
or β-actin were used as loading controls.
To detect secreted osteopontin (sOPN), proteins in 5ml conditioned
media were incubated with 10 μl StrataClean Resin (Agilent Technologies,
Santa Clara, CA, USA) and rotated for 1–2 h at 4 °C. After brief
centrifugation, the pellet was resuspended in lysis buffer (125mM Tris-
HCl pH 6.8, 0.2% SDS, 20% glycerin, and 1× Complete Protease Inhibitor
Cocktail) and samples were incubated for 5 min at 95 °C. Lysates were
adjusted to 100mM DTT and 0.01% bromphenol blue, then 10 μg of total
protein (measured with the BCA method) were loaded onto SDS-PAGE gels
and Western blotted.
The following antibodies were used for immunoblotting: anti-mouse
IER2 (clone 1A2, [13]); anti-human IER2 (ARP34401_P050) from Aviva
Systems Biology (San Diego, CA, USA); osteopontin (OPN, #AF808) from
R&D Systems (Mineapolis, MN, USA); vinculin (#V9131), MDM2 (3G9,
04–1530), and β-actin (AC-15, #A5441) from Merck (Darmstadt, Germany);
p16INK4A (p16, ab189034) and p21WAF1/Cip1 (p21, EPR3993, ab109199)
from Abcam (Cambridge, MA, USA); p27KIP1 (p27, F-8, sc-1641), p21WAF1/
Cip1 (p21, C-19, sc-397), ERK1 (ERK, C-16, sc-93), AKT1/2/3 (AKT, H136, sc-
8312), MDM2 (SMP14, #sc-965), and p53 (DO-7, sc-47698) from Santa Cruz
Biotechnology (Dallas, TX, USA); p53 (1C12, #2524), p53-pS15 (D4S1H,
#12571), Rb-pS807/811 (D20B12 XP), Rb (D20), AKT-pS473 (587F11,
#4051), AKT-pT308 (D25E6, #13038), ERK1/2-pT202/pY204 (#9101),
GAPDH (14C10, #2118), mTOR (#2972) and mTOR-pS2448 (#2971) from
Cell Signaling Technology (Danvers, MA, USA); and p53-pS392 (FP3.2,
#629501) from BioLegend (San Diego, CA, USA). Anti-rabbit and anti-
mouse IgG-HRP secondary antibodies produced in goat, and anti-goat
secondary antibody produced in rabbit were purchased from Dako
(Hamburg, Germany). Antibodies were diluted in PBS containing 2.5%
skimmed milk and 0.1% Tween (Carl Roth, Karlsruhe, Germany) according
to the respective manufacturer’s instructions. Quantification of Western
blots was performed in ImageJ/Fiji [100]. Protein expression was calculated
as the integrated density of each band normalized to the average of
control-treated samples.
Quantitative real-time PCR (qRT-PCR)
Total RNA was isolated using TRIzol reagent (Thermo Fisher Scientific,
Waltham, MA, USA), following the manufacturer’s instructions. RNA
(1–2 μg) was treated with RNase-free DNase I, followed by EDTA
deactivation for 10min at 65 °C (both from Thermo Fisher Scientific,
Waltham, MA, USA). First-strand cDNA was synthesized with random
hexamer primers, using dNTP mix and RevertAid H Minus Reverse
transcriptase (all from Thermo Fisher Scientific, Waltham, MA, USA). qRT-
PCR was performed in a Stratagene Mx3500P qPCR machine (Agilent, Santa
Clara, CA, USA) using SYBR Select Master Mix containing SYBR Green dye
(Applied Biosystems, Foster City, CA, USA). The relative quantity of cDNA
was estimated using the ΔΔCT method, and data were normalized to
RPLP0 or GAPDH.
The following mouse forward and reverse primers, purchased from
Metabion (Steinkirchen, Germany), were used for qRT-PCR: IER2: 5′-TAC
CTC TCA GCC AAG GTA GA-3′, 5′-TCC TCT TGC GTA TCC ATG GG-3′; IL-6: 5′-
TAC CAC TTC ACA AGT CGG AGG C-3′, 5′-CTG CAA GTG CAT CAT CGT TGT
TC-3′; CXCL15: 5′-GGT GAT ATT CGA GAC CAT TTA CTG-3′, 5′-GCC AAC AGT
AGC CTT CAC CCA T-3′; OPN: 5′-GCT TGG CTT ATG GAC TGA GGT C-3′, 5′-
CCT TAG ACT CAC CGC TCT TCA TG-3′; IL23a: 5′-CAT GCT AGC CTG GAA
CGC ACA T-3′, 5′-ACT GGC TGT TGT CCT TGA GTC C-3′; CCL5: 5′-CCT GCT
GCT TTG CCT ACC TCT C-3′, 5′-ACA CAC TTG GCG GTT CCT TCG A-3′; TP53:
5′-GCA TGA ACC GCC GAC CTA TCC-3′, 5′-CAG GGC AGG CAC AAA CAC
GAA C-3′; RPLP0: 5′-GGA CCC GAG AAG ACC TCC TT-3′, 5′-GCA CAT CAC
TCA GAA TTT CAA TGG-3′.
The following human forward and reverse primers, purchased from
Metabion (Steinkirchen, Germany) were used for qRT-PCR: IER2: 5′-AGT
GCA GAA AGA GGC ACA GC-3′, 5′-ACC TTG GCC GAG AGG TAG AG-3′; OPN:
5′-CTG ACA TCC AGT ACC CTG ATG C-3′, 5′-GGC CTT GTA TGC ACC ATT CA-
3′; TP53: 5′-CAG CAC ATG ACG GAG GTT GT-3′, 5′-TCA TCC AAA TAC TCC
ACA CGC-3′; GAPDH: 5′-CGA CCA CTT TGT CAA GCT CA-3′, 5′-AGG GGT
CTA CAT GGC AAC TG-3′.
The data are expressed as the means+ SEM from 3 to 5 biological
replicates, analyzed in technical duplicates.
RNA interference
Small interfering RNAs (siRNA) targeting mouse OPN (siOPN, s74322,
#4390771) were purchased from Thermo Fisher Scientific (Waltham, MA,
USA). Silencer Select Negative Control No. 1 siRNA (Thermo Fisher
Scientific, #4390843) was used as a control. Mouse Trp53 was targeted
using ON-TARGETplus SMARTpool siRNA (L-040642-00-0005) and ON-
TARGETplus Non-targeting Control Pool siRNA (D-001810-10-05) as control
(Horizon Discovery, Cambridge, UK). OPN siRNAs were introduced into the
cells using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA), while
Trp53 siRNAs were transfected at a final concentration of 25 nM using
Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA),
following the manufacturer’s instruction.
Cytokine array
Gene expression was analyzed in three independent experiments using
the mouse Cancer Inflammation and Immunity Crosstalk Array (PAMM-
181Z, Qiagen Sciences, Germantown, MD, USA) according to the
manufacturer’s instructions.
Indirect immunofluorescence
Cells grown on glass coverslips were washed with PBS, fixed with 100%
ice-cold methanol (AppliChem, Darmstadt, Germany) for 10min at −20 °C,
then permeabilized using 0.1% Triton X-100 (Carl Roth, Karlsruhe,
Germany) for 10min at room temperature (RT). After washing with PBS,
cells were incubated in 10% FBS/PBS for 30min to block unspecific
binding. Cells were incubated with IER2 antibody (ARP34401_P050; Aviva
Systems Biology, San Diego, CA, USA) diluted 1:500 in blocking solution for
3 h at RT, then extensively washed with PBS. Incubation with the goat anti-
rabbit AlexaFluor 546 (Thermo Fisher Scientific, Waltham, MA, USA)
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secondary antibody (1:1000) was performed for 1 h at RT. Cell nuclei were
counterstained with 1 μg/ml DAPI (AppliChem, Darmstadt, Germany) for
5 min at RT, and coverslips were mounted in Fluoromount mounting
medium (SouthernBiotech, Birmingham, AL, USA). Fluorescent signals were
captured using a Zeiss Axio Imager D1 microscope equipped with an
AxioCam MRm camera and AxioVision 4.7 software (Carl Zeiss, Oberko-
chen, Germany).
Immunohistochemistry
Formalin-fixed, paraffin-embedded 5 μm-thick tumor sections were used
for immunohistochemical staining. Deparaffinization in Roti-Histol (Carl
Roth, Karlsruhe, Germany) and dehydration in 100–70% EtOH was followed
by 30min heat-induced antigen retrieval (Target Retrieval Solution pH 6.1;
Dako, Hamburg, Germany). Endogenous peroxidase was quenched with
hydrogen peroxide (3%, 5 min, Roth, Karlsruhe, Germany), and unspecific
antibody binding was blocked using 10 % goat or rabbit serum in 1% BSA/
PBS for 1 h at RT. Samples were then incubated with IER2 (ARP-
34401_P050; 1:500) from Aviva Systems Biology (San Diego, CA, USA);
p53 (DO-7; 1:150) and p21WAF1/Cip1 (p21, C19; 1:800) from Santa Cruz
Biotechnology (Dallas, TX, USA), and OPN antibody (AF808; 1:100) from
R&D Systems (Minneapolis, MN, USA) at 4 °C overnight. After washing 3x
with PBS, slides were incubated with biotinylated secondary antibody for
1 h at RT (Dako, Hamburg, Germany). Antibody staining was detected
using the VECTASTAIN ABC kit and the VECTOR NovaRed peroxidase
substrate kit (both from Vector Laboratories, Burlingame, CA, USA).
Sections were counterstained with hematoxylin (Merck, Darmstadt,
Germany). All primary antibodies were titrated and specificity-tested
through negative controls (without primary antibody) prior to their use for
TMAs. Tumors derived from MMTV-PyMT mice were used as a positive
control for the anti-osteopontin antibody. Visualization of melanoma cells
was performed by staining against S100B (Abcam, Cambridge, UK) as
described [101].
For scoring of IER2-, OPN-, and p21-stained TMAs, a quantity-/intensity-
based IHC scoring system was applied, using the following formula:
percentage of IER2/OPN positive cells among the S100B-positive cells
(0–4) × intensity score (0–4) (see Fig. S8A). Nuclear positivity for p53 was
assessed based on the percentage of p53-positive cells per punch using a
10% cutoff (≤10% tumor cells staining= negative, ≥10%= positive) as
previously described [102]. Images of stained tumor sections and TMAs
sections were captured using a Zeiss Axio Imager Z1 microscope equipped
with an AxioCam HRc camera and AxioVision 4.8 software (Carl Zeiss,
Oberkochen, Germany). Image acquisition and scoring were performed in
a blind fashion by two independent experimenters (L.K. and S.D.S.), in the
majority of cases from duplicate stainings. Low-quality IER2- and OPN-
stained specimens were excluded from the analysis, which resulted in
differing total numbers of specimens analyzed. For each sample, the
average score of the two experimenters was used.
Flow cytometry and cell sorting
To analyze cell cycle and ploidy status of 3T3-ind-IER2 #11, B16-ind-IER2 #51,
B16-ind-IER2-mNLS #56 cells, and Ret-ind-IER2 #69 cells, 1.2 × 105 cells were
seeded into 6-well plates and treated with three doses of DMSO or 0.2–5 μM
RSL every 24 h. Cells were detached with PBS/5mM EDTA (5–10min/37 °C),
resuspended in PBS with 1mMMgCl2, and centrifuged for 3min at 1200 rpm.
Pelleted cells were resuspended in 150 μl of 10% FBS/PBS and mixed drop-
wise with ice-cold 70% EtOH. After overnight incubation at −20 °C, cells were
centrifuged for 5min at 1500 rpm, resuspended in 250 μl PBS containing 1 μl
DRAQ5 fluorescent probe (5mM; Thermo Fisher Scientific, Waltham, MA,
USA) and incubated for 20min at RT. Cells were diluted 1:1 with PBS and
subjected to flow cytometry analysis using a BD FACSCanto II (BD
Biosciences, Franklin Lakes, NJ, USA). Doublets and dead cells were excluded
from the analysis. Flow cytometry data were analyzed using FlowJo 7.6.5
cytometry analysis software (FlowJo, LLC).
To enrich the senescent fraction in IER2-expressing B16 and Ret cells,
cells were treated with 3 × 0.5 and 5 μM RSL, respectively. Six hours after
the last RSL treatment, senescent and non-senescent cells were sorted
using a BD FACSARIA IIu based on forward and sideward scattering,
collected in RSL-containing PBS, and immediately processed for qRT-PCR
or western blot analysis. In experiments in which cells were treated with
either DMSO or RSL also after the cell sorting, 1 × 105 sorted cells were
seeded onto a 12-well plate, left to attach overnight, then treated with RSL
or DMSO for additional 3 days, and subsequently processed for SA-
β-galactosidase staining. After each sorting, the viability and purity of the
sorted fractions were evaluated.
Senescence-associated β-galactosidase activity assay
Senescence-associated β-galactosidase (SA-β-gal) activity was detected as
previously described [34]. Briefly, 1 × 104 cells/cm2 were seeded in triplicate
into 12- to 24-well plates. For knockdown experiments, the cells were
transfected immediately with siRNA. After overnight attachment, cells were
treated daily with either DMSO or 0.25–5.0 μM RSL. Six hours after the last
dose, cells were washed with PBS, fixed for 15min at RT with a 2%
formaldehyde/0.2% glutaraldehyde solution, then incubated overnight at
37 °C in a non-CO2 atmosphere with X-Gal staining solution (40mM citric acid
pH 6.0, 5mM potassium hexacyanoferrate II, 5mM potassium hexacyanofer-
rate III, 150mM NaCl, and 2mM MgCl2) containing 1mg/ml X-β-gal substrate
(Carl Roth, Karlsruhe, Germany). Cells were extensively washed with PBS and
imaged with a Leica DMI6000B inverted microscope equipped with a DCF420
C camera and LAS X Core software (Leica Microsystems, Wetzlar, Germany).
The percentage of SA-β-gal-positive cells from total cells was calculated for
three biological replicates. Images were captured using a Zeiss Axio Imager
Z1 microscope equipped with an AxioCam HRc camera and AxioVision
4.8 software (Carl Zeiss, Oberkochen, Germany).
Proliferation assays
Proliferation assays were performed using the CyQUANT NF Cell Proliferation
Assay Kit (Molecular Probes, Invitrogen/Thermo Fisher Scientific, Waltham, MA,
USA). Cells were seeded in a 96-well plate at a density of 1 × 103 cells/well in
four biological replicates and treated daily with RSL or an equivalent volume of
DMSO for two days. Cell density was measured 4 h post-seeding (effective
“time 0”), as well as 24 and 48 h after the first measurement. The assay was
performed according to the manufacturer’s instructions. Measurement of
fluorescence was detected at 530 nm using the Infinite 200 plate reader (Tecan
Group Ltd., Zürich, Switzerland). Data were calculated as the average fold
increase in fluorescence at 24 and 48 h, normalized to fluorescence at 0 h.
Cell viability assay
To determine cell viability after IER2 induction, 3T3-ind-IER2 #11 cells were
treated daily with 0.5 μM RSL or an equal volume of DMSO for three
consecutive days. Cells were detached 24 h after the last dose using 0.05%
Trypsin–EDTA (Gibco, Carlsbad, CA, USA), resuspended in the growth
medium, stained 1:1 with 0.4% Trypan Blue solution (Merck, Darmstadt,
Germany) and counted with a hemocytometer.
Migration assay
Cell exclusion zone migration assays were performed in four biological
replicates using two-well silicone inserts (Ibidi, Martinsried, Germany). Cell
suspension, 4 × 105 cells/ml in 70 μl, were added to each well of the insert
and allowed to grow to confluence overnight. Inserts were removed and
images captured 0, 8, 24, and 30 h after removal. Cells were treated with
RSL or DMSO at 0, 8, 24 h post-insert removal.
To assess migration of B16–F10 cells or melanocytes in the presence of
conditioned media, B16 IER2 mNLS-inducible cells or IER2-wt-inducible cells
with or without the expression of osteopontin were seeded around the
inserts 36 h before removal of the inserts, and subsequently treated twice
per day with RSL or the equivalent volume of DMSO. After 24 h, 70 µl of a
4 × 105 cells/ml suspension of B16–F10 parental (non-inducible), Melan-a or
Mel-STV cells were added to each well of the insert and allowed to grow to
confluence overnight. Inserts were removed. Images were captured 0 h and
7–32 h after insert removal at 10x magnification using a Leica DMI6000B
inverted microscope equipped with a DCF420 C camera and LAS X Core
software (Leica Microsystems, Wetzlar, Germany). Wells was marked to
ensure that the same area was imaged at each time point. Images were
analyzed using the Fiji/ImageJ software [100], and the wound area was
determined with the MRI Wound Healing Tool macro (http://dev.mri.cnrs.fr/
projects/imagej-macros/wiki/Wound_Healing_Tool). The migrated area was
calculated as the change in wound area.
Transwell invasion assays
Invasion assays were performed in triplicate using Corning Costar Transwell cell
culture inserts with 8 µM pores (Sigma-Aldrich/Merck, Darmstadt, Germany).
Inserts were coated with 55 µl of 0.6–0.8mg/ml High Concentration Corning
Matrigel Matrix (Corning, NY, USA), which was allowed to solidify for 4 h at
37 °C. Each insert was seeded with 6 × 104 cells in a medium containing 1%
FBS, then were allowed to invade toward a medium containing 10% FBS for
64 h. Cells were treated with 3 × 0.5 μM (IER2-wt and OPN-KOs) or 30 μM
(IER2-mNLS) RSL or an equivalent volume of DMSO twice per day. For
invasion assays with conditioned media, CM was prepared by growing
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cells in a medium containing 1% FBS for 48 h, and treating the cells with
3 × 0.5 μM (IER2-wt and OPN-KOs) or 30 μM (IER2-mNLS) RSL, or an
equivalent volume of DMSO. Transwell inserts were coated as mentioned
above. Twenty-four-hour prior to seeding cells in transwell inserts, 1 ×
105 inducible cells were seeded in a medium containing 10% FBS to the
base of the well and treated with RSL or DMSO once per day. Non-
inducible B16, Melan-a or Mel-STV cells (6 × 104) were seeded onto the
transwell membrane in CM with 1% FBS (Melan-a, Mel-STV cells) or a
mixture of CM and fresh medium containing 1% FBS (1:1, B16 cells) and
allowed to invade across the membrane for 48 h.
After the invasion, cells were either fixed with methanol and stained
with 0.1 mg/ml crystal violet or fixed with 70% ethanol and stained with
DAPI (5 μg/ml). Inserts stained with crystal violet were incubated in 10%
acetic acid to extract the crystal violet stain, and optical density was
measured at 595 nm. The degree of invasion was calculated as the average
fold difference in optical density or normalized DAPI-stained area of RSL
treated samples compared to DMSO treated samples.
Soft-agar assay
For the soft-agar assay, 1.5 ml of 0.5% Noble Agar (BD Biosciences, Franklin
Lakes, NJ, USA) in DMEM were plated into 6-well plates and allowed to
solidify at RT for at least 5 min. Soft agar at a concentration of 0.3–0.35%
was prepared by dilution of 2% Noble Agar in conditioned DMEM medium
of B16 IER2-ind #51 cells treated daily for three consecutive days with
either 0.5 μM RSL or an equivalent volume of DMSO. Two millilitre of this
dilution containing 1000–5000 cells/ml was layered on top of the bottom
agar. Cells were fed twice per week with 500 μl CM and allowed to grow for
2–3 weeks. Colonies were fixed and stained with 0.005% crystal violet, 1%
PFA, and 1% methanol for 1 h, imaged using a Fusion FX Imager (Vilber,
Marne-la-Vallée, France), and quantified using ImageJ/Fiji [100].
Clinical data set analysis
The cBioportal for Cancer Genomics (http://www.cbioportal.org/ [103] was
used to access and download the TCGA Skin Cutaneous Melanoma Dataset
containing RNA-Seq expression and clinical data of 471 melanoma patients
(TCGA, provisional). The cutoff between IER2high and IER2low tumors was set at
a z-score of 1.5. The difference between Kaplan–Meier curves was analyzed
using the log-rank (Mantel–Cox) test. TP53, BRAF, and NRAS mutational data
from whole-exome sequencing from 362 patients were correlated with IER2
expression. Significance was determined using the unpaired Student’s t test.
Gene expression analysis
RNA was isolated with RNAPure, peqGOLD (Peqlab, Erlangen, Germany).
RNA was tested by capillary electrophoresis on an Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA) and high quality was
confirmed. Gene expression profiling was performed using arrays of
mouse Mm430_2.0-type from Affymetrix (Thermo Fisher Scientific,
Waltham, MA, USA). Biotinylated antisense cRNA was then prepared from
33 ng/µl RNA according to the Affymetrix standard labeling protocol with
the GeneChip WT Plus Reagent Kit and the GeneChip Hybridization, Wash
and Stain Kit (both from Affymetrix, Santa Clara, USA). Afterward, the
hybridization on the chip was performed on a GeneChip Hybridization
oven 640, then dyed in the GeneChip Fluidics Station 450 and thereafter
scanned with a GeneChip Scanner 3000. All of the equipment used was
from Affymetrix (High Wycombe, UK). A Custom CDF Version 10 with
ENTREZ-based gene definitions was used to annotate the arrays [104]. The
raw fluorescence intensity values were normalized by applying quantile
normalization and RMA background correction. One-way ANOVA was
performed to identify differentially expressed genes using the commercial
software package SAS JMP10 Genomics, version 4, from SAS (SAS Institute,
Cary, NC, USA). A nominal p-value was taken as the level of significance.
GSEA was used to determine whether defined lists (or sets) of genes
exhibit a statistically significant bias in their distribution within a ranked
gene list using the software GSEA [35]. Pathways belonging to various cell
functions were obtained from public external databases (KEGG, http://
www.genome.jp/kegg; Gene Ontology Consortium, biological processes
annotations, http://www.geneontology.org/). All analyses were done using
three biological replicates. The microarray data have been deposited in
Gene Expression Omnibus (GEO) with accession number GSE181200.
Statistics
Where appropriate, figure legends define the number of biological
replicates (n). Results are represented as the mean+ SEM (standard error
of the mean). For each in vitro experiment, n represents the number of
individual biological replicates. Graphs for qRT-PCR experiments represent
data from n ≥ 3 biological replicates, with each biological replicate being
executed in two technical replicates. For TCGA Skin Cutaneous Melanoma
Dataset analysis, n= number of individual patients. For melanoma TMAs
analysis, n= number of analyzed specimens. For experiments comparing
two groups, the significance was evaluated using a two-tailed unpaired
Student’s t test. Asterisks correspond to p-values below the following
thresholds: *p < 0.05; **p < 0.01; ***p < 0.001; n.s. (non-significant) denotes
cases where the significance threshold was not reached (p > 0.05). For
Kaplan Meier survival analysis, significant differences were determined
using the log-rank (Mantel–Cox) test. Linear regression (R2) analysis was
used to assess the correlation between IER2 and OPN expression in clinical
samples. Sample sizes were chosen based on previous experience with
analogous experiments. Randomization was not applied. All statistics were
performed with Microsoft Excel 2010 (Microsoft, Redmond, WA, USA) or
GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA). Microscopy
images related to in vitro experiments are representative of three
biological replicates.
Study approval
This study was performed in accordance with the ethical votes of the
Medical Ethics Committee of the Medical Faculty Mannheim, University of
Heidelberg (permit numbers: 2010-318N-MA and 2014-835R-MA). The
study followed the guidelines of the Declaration of Helsinki, and patient
identity and pathological specimens remained anonymous in the context
of the study.
Human melanoma TMA was generated at the core facility of the National
Center for Tumor Diseases, Department of Pathology, University of Heidelberg,
as described previously [105, 106]. Information about the specimens and
patients contributing to the TMA can be found in Tables S4 and S5.
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